Cell­tri­on teams up with an­oth­er Ko­re­an bio­phar­ma in an­ti­body dis­cov­ery deal

Two Ko­re­an com­pa­nies have signed a joint R&D dis­cov­ery agree­ment, with the po­ten­tial to earn in the nine-fig­ures.

Clin­i­cal-stage bio­phar­ma Genuv has part­nered up with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.